Pluripotent Stem Cell Renal Differentiation via Defined Media
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into renal precursor cells and podocytes are inefficient, resulting in heterogeneous populations, low yields, and require undefined components, making them unsuitable for large-scale drug discovery and regenerative medicine applications.
Innovation Solution
A chemically defined method involving specific small molecule inhibitors and growth factors is used to differentiate pluripotent stem cells into renal precursor cells expressing SIX2, WT1, and SALL1, followed by modulation to fully differentiated podocytes, eliminating the need for embryoid bodies and improving reproducibility and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional differentiation methods are used, then renal precursor cells can be generated, but the yield is low and the population is heterogeneous
Solution Approach 1:
The patent applies parameter changes by systematically modifying culture medium composition (switching from serum-containing to serum-free media), growth factor concentrations (BMP4, BMP7, Activin A), and small molecule additions (CHIR99021, SB431542) to achieve precise control over differentiation stages. This resulted in homogeneous Six2+ renal precursor cells with up to 95% purity and consistent differentiation efficiency across batches.
Solution Approach 2:
The patent uses intermediary substances including defined small molecule inhibitors (CHIR99021 for GSK3β, SB431542 for TGFβ receptor), growth factors (BMP4, BMP7, Activin A), and serum-free medium formulations as mediators to direct and control the differentiation process. These intermediaries enable precise temporal and spatial control of gene expression patterns during renal lineage specification.
2Ease of manufacture
If conventional methods are used, then differentiation can proceed, but undefined components are required making scalability difficult
Solution Approach 1:
The patent transitions from undefined serum-based systems to fully chemically defined serum-free media with specified concentrations of growth factors and small molecules. This parameter specification enables exact reproduction of differentiation conditions across different laboratories and scales, eliminating batch variability and facilitating GMP-compliant manufacturing.
Solution Approach 2:
The patent employs disposable microplate culture systems with pre-defined medium formulations that can be easily prepared and discarded. The standardized, single-use culture plates with defined medium compositions enable high-throughput screening and scalable production without requiring complex, expensive, and difficult-to-maintain bioreactor systems.
3Productivity
If conventional differentiation protocols are used, then renal cells can be obtained, but the process is time-consuming
Solution Approach 1:
The patent applies preliminary action by pre-treating pluripotent stem cells with CHIR99021 (GSK3β inhibitor) and other preparatory factors before initiating the main differentiation sequence. This priming step primes the cells for rapid and efficient entry into the renal lineage, reducing the overall differentiation time while maintaining high purity and functionality of the final renal precursor cells.
Solution Approach 2:
The patent implements continuous differentiation action through sequential medium changes and sustained exposure to differentiation factors without unnecessary interruptions. The protocol maintains optimal differentiation conditions continuously, avoiding the time losses associated with repeated passaging, thawing, or suboptimal condition adjustments, thereby accelerating the production of renal precursor cells.
Data Source
AI summary
This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.